{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-015503","form_type":"8-K","ticker":"INBP","cik":"0001016504","company_name":"INTEGRATED BIOPHARMA INC","filed_at":"2022-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.322688+00:00","generated_at":"2026-06-25T00:12:36.042163+00:00","sec_items":["9.01","5.07"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Integrated BioPharma appoints Damon DeSantis to Board, replacing Carl DeSantis","bullets":["Carl DeSantis resigned as Class I Director on June 20, 2022; no disagreement cited.","Damon DeSantis appointed to fill vacancy, will serve as Class I Director until 2024.","Damon is son of Carl DeSantis, a principal shareholder, and serves on boards of MacPherson's and Celsius Holdings (CELH).","Damon received a stock option for 50,000 shares at closing price on June 27, 2022, vesting quarterly through June 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-015503","json":"https://secwatch.observer/filing/0001437749-22-015503.json","markdown":"https://secwatch.observer/filing/0001437749-22-015503.md","text":"https://secwatch.observer/filing/0001437749-22-015503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922015503/0001437749-22-015503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1016504/000143774922015503/inbp20220620_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T00:12:36.042163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}